SCHEMBL1763241

SCHEMBL1763241

CNCc1cc(-c2ccsc2)n(S(=O)(=O)c2ccc(F)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.41
HTR6 P50406 10/20 0.35
GNRHR P30968 1/20 0.34
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34
IDH2 P48735 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33
TUBA3E Q6PEY2 1/20 0.33
TUBA1A Q71U36 1/20 0.33
TUBA1C Q9BQE3 1/20 0.33
TUBB6 Q9BUF5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1157287 0.99 PRMT6 (0.41) PRMT6HTR6GNRHRSLC1A3SLC1A2
SCHEMBL1156256 0.89 PRMT6 (0.46) PRMT6HTR6SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL1156593 0.88 PRMT6 (0.45) PRMT6HTR6SLC1A3SLC1A2SLC1A1
SCHEMBL1156588 0.87 CHRNA7 (0.37) HTR6ALDH3A1PTGS2
SCHEMBL1156132 0.84 ELAVL1 (0.42) HTR6CYP3A4CYP2D6ALDH3A1
SCHEMBL1157041 0.83 ALDH1A1 (0.42) PTGS2
SCHEMBL1763110 0.83 PRMT6 (0.45) PRMT6PTGS2
Hydrochloric Acid SCHEMBL1156643 0.82 PRMT6 (0.44) PRMT6PTGS2
SCHEMBL1762992 0.82 PRMT6 (0.44) PRMT6HTR6CYP3A4
SCHEMBL1581182 0.81 PKM (0.40) HTR6ALDH3A1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9186411-B2 Pharmaceutical composition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-17 US disclosed
US-20130261156-A1 PHARMACEUTICAL COMPOSITION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-03 US disclosed
EP-2564833-A1 Photostabilized pharmaceutical composition Takeda Pharmaceutical Company Limited (JP) 2013-03-06 EP disclosed
US-20110124687-A1 PHARMACEUTICAL COMPOSITION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124687-A1 PHARMACEUTICAL COMPOSITION CYP2C19, MLST8, CYP3A43 PRMT6 4087/4885HTR6 1727/4885GNRHR 3033/4885
US-20130261156-A1 PHARMACEUTICAL COMPOSITION CYP2C19, MLST8, CYP3A43 PRMT6 4087/4885HTR6 1727/4885GNRHR 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.